Siemens Sets 2027 Shareholder Vote for Major Healthineers Stake Reduction

Siemens schedules a 2027 shareholder vote to spin off 30% of Siemens Healthineers, reducing its stake to a minority holding. The move awaits a final tax ruling.

Siemens has locked in the timeline for a fundamental corporate overhaul, scheduling a shareholder vote for February 2027 to approve the spin-off of a significant stake in its medical technology unit. The move will see the industrial giant relinquish its majority holding in Siemens Healthineers, a strategic shift years in the making.

The core of the transaction is a direct transfer of approximately 30 percent of Healthineers shares to existing Siemens stockholders. This will reduce Siemens's current 67 percent majority stake to a minority financial holding, a process structured under German transformation law. While regulatory groundwork is advanced, the final green light hinges on a pending tax ruling from authorities to ensure the spin-off can be executed on a tax-neutral basis. This official tax assessment remains the critical, unresolved step in the formal process.

This strategic pivot aligns with Siemens's sharper focus on its core technology operations. Management is steering the conglomerate toward automation, industrial digitalization, and smart building infrastructure, with medical technology now positioned outside this central scope. The plan, first announced in November 2025, requires more patience from investors than some initially hoped, as market observers had previously speculated about a faster execution.

Market reactions to the confirmed timeline have been muted. Siemens's share price showed resilience, trading around 240 euros in XETRA trading, comfortably above its 200-day moving average. The stock has gained roughly 28 percent over the past twelve months, suggesting investors may view the separation as a value driver for the parent company. Analyst opinions on the pace are mixed. RBC Capital Markets maintains its 270 euro price target for Siemens but notes the delayed 2027 vote could disappoint impatient shareholders.

The environment for Healthineers shares is more challenging. Morgan Stanley recently cut its price target on the stock to 41 euros with an "Equal Weight" rating. Healthineers shares last traded at 38.91 euros, down approximately 14 percent since the start of the year. In a separate operational move, Healthineers recently participated with Insight Partners in a $16 million funding round for ScreenPoint Medical, a Dutch specialist in AI-supported early breast cancer detection, underscoring its focus on artificial intelligence in healthcare.

The entire ambitious plan now moves toward its decisive milestone: the shareholder meeting in early 2027. Its successful completion remains contingent on securing the crucial tax approval from German financial authorities in the intervening period.